Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 6

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia

Authors El Rassi F, Khoury HJ

Received 3 May 2013

Accepted for publication 30 May 2013

Published 5 August 2013 Volume 2013:6 Pages 57—62

DOI https://doi.org/10.2147/PGPM.S32145

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Fuad El Rassi, Hanna Jean Khoury

Division of Hematology, Department of Hematology and Medical Oncology, the Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Abstract: Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for the treatment of chronic myeloid leukemia. This review of bosutinib summarizes the mode of action, pharmacokinetics, efficacy and safety data, as well as the patient-focused perspective through quality-of-life data. Bosutinib has shown considerable and sustained efficacy in chronic myeloid leukemia, especially in the chronic phase, with resistance or intolerance to prior tyrosine kinase inhibitors. Bosutinib has distinct but manageable adverse events. In the absence of T315I and V299L mutations, there are no absolute contraindications for the use of bosutinib in this patient population.

Keywords: bosutinib, chronic myeloid leukemia, treatment, review, SRC-ABL kinase inhibitor, clinical activity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]